نتایج جستجو برای: 177

تعداد نتایج: 9516  

Journal: :Journal of clinical microbiology 2005
Lothar Beutin Qingke Kong Lu Feng Quan Wang Gladys Krause Luciana Leomil Qi Jin Lei Wang

Escherichia coli O 174 and O 177 are newly described O serogroups which were reported as human pathogens. Identification of these strains by serotyping has been restricted, as the required sera are not commercially available. In this study, a collection of 13 E. coli O 174 strains and 12 E. coli O 177 strains was studied on the O:H serotypes and virulence markers. The O-antigen gene clusters of...

Introduction: Rheumatoid arthritis (RA) is the most common autoimmune disease, leading to the destruction of the joints and causing pain, disability, and immobility in the patients. Radiosynovectomy (RSV) has been applied as an effective treatment for the patients with resistant synovitis after failure of long-term pharmacotherapy and intra-articular steroid injection for more than 50 years. Se...

قنادی مراغه, محمد, یاوری, کمال,

  زمینه و هدف: آنتی­بادی منوکلونال سیتوکسیمب به گیرنده فاکتور رشد اپیدرمال متصل می­شود، بنابراین امکان ایجاد روش­های تشخیصی و درمانی از طریق این گیرنده را فراهم می­آورد. در این مطالعه قابلیت سیتوکسیمب جهت تولید یک رادیوداروی جدید مورد بررسی قرار گرفت و تست­های کنترل کیفی آزمایشگاهی و حیوانی به عنوان گام اول در تولید رادیوداروی جدید انجام شدند.   روش کار: سیتوکسیمب با استفاده از اولترا فیلتر -15...

ژورنال: بیماری های پستان 2014
رسانه, سمیرا, یاوری, کمال,

چکیده مقدمه: هرسپتین یک آنتی‌بادی مونوکلونال است که برای درمان سرطان پستان مورد استفاده قرار می‌گیرد. در این مطالعه هرسپتین با لوتشیم-177 نشان‌دار شده و بعد از انجام کلیه تست‌های کنترل کیفی، اثر درمانی آن روی سرطان پستان موش مورد ارزیابی قرار گرفته است. روش بررسی: هرسپتین به کمک شلاتور DOTA با لوتشیم نشان‌دار شد. کلیه تست‌های کنترل کیفی شامل بازده نشان‌دارسازی، بررسی پایداری در ب...

Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report...

2014
Jiyun Shi Di Fan Chengyan Dong Hao Liu Bing Jia Huiyun Zhao Xiaona Jin Zhaofei Liu Fang Li Fan Wang

PURPOSE Targeted radiotherapy (TRT) is an emerging approach for tumor treatment. Previously, 3PRGD2 (a dimeric RGD peptide with 3 PEG4 linkers) has been demonstrated to be of advantage for integrin αvβ3 targeting. Given the promising results of (99m)Tc-3PRGD2 for lung cancer detection in human beings, we are encouraged to investigate the radiotherapeutic efficacy of radiolabeled 3PRGD2. The goa...

2012
Cristina Cruz-Hernandez Sagar K. Thakkar Julie Moulin Manuel Oliveira Isabelle Masserey-Elmelegy Fabiola Dionisi Frédéric Destaillats

In the present study, we used a preclinical model of induced lipolytic enzyme insufficiency, and hypothesized that the use of monoacylglycerols (MAG) will enhance their bioavailability and delivery to the tissues. Experimental diets containing 20% lipids were fed to rats for 21 days with or without Orlistat. The control diet of fish oil (FO), a source of EPA and DHA, was tested against: structu...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2013
Scott T Tagawa Matthew I Milowsky Michael Morris Shankar Vallabhajosula Paul Christos Naveed H Akhtar Joseph Osborne Stanley J Goldsmith Steve Larson Neeta Pandit Taskar Howard I Scher Neil H Bander David M Nanus

PURPOSE To assess the efficacy of a single infusion of radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; (177)Lu) by prostate-specific antigen (PSA) decline, measurable disease response, and survival. EXPERIMENTAL DESIGN In this dual-center phase II study, two cohorts with progressive metastatic castration-resistant prostate cancer received on...

2014
Johanna Dalmo Emelie Westberg Lars Barregard Lisa Svedbom Martin Johansson Margareta Törnqvist Eva Forssell-Aronsson

BACKGROUND The kidneys are regarded as one of the main dose-limiting organs in the treatment of neuroendocrine tumours with (177)Lu-[DOTA(0), Tyr(3)]-octreotate ((177)Lu-octreotate), despite the successful use of kidney uptake blocking agents such as lysine and arginine. To avoid renal toxicity but still give each patient as high amount of (177)Lu-octreotate as possible, there is a need for met...

2013
F. Guerriero M. E. Ferrari F. Botta F. Fioroni E. Grassi A. Versari A. Sarnelli M. Pacilio E. Amato L. Strigari L. Bodei G. Paganelli M. Iori G. Pedroli M. Cremonesi

Kidney dosimetry in (177)Lu and (90)Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is considered time and resource consuming. We investigated the most adequate timing for imaging and time-activity interpolating curve, as well as the performance of a simplified dosimetry, by means of just 1-2 scans. Finally the influence of risk factors and of the pepti...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید